PharmaShots | Incisive News in 3 Shots

Subscribe Now

Blastic Plasmacytoid Dendritic Cell Neoplasm

$ImmunoGen's IMGN632 Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm$

ImmunoGen's IMGN632 Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Blastic Plasmacytoid Dendrit...

October 5, 2020

FDA Approves Elzonris (tagraxofusp)- the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy

FDA Approves Elzonris (tagraxofusp)- the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted...

December 31, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us